- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
Temsirolimus
別名：NSC 683864,CCI-779
Temsirolimus is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
CAS No. 162635-04-3
文献中Selleckの製品使用例（98）
製品安全説明書
現在のバッチを見る：
純度：
99.96%
99.96
Temsirolimus関連製品
シグナル伝達経路
mTOR阻害剤の選択性比較
Cell Data
| Cell Lines | Assay Type | Concentration | Incubation Time | 活性情報 | PMID |
|---|---|---|---|---|---|
| A498 | Cytotoxicity assay | 6 days | Cytotoxicity against human A498 cells assessed as inhibition of cell viability after 6 days by MTT assay, IC50 = 0.5 μM. | 23360104 | |
| A498 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A498 cells after 72 hrs by MTT assay, IC50 = 0.35 μM. | 25124114 | |
| human LNCAP cells | Proliferation assay | 3 days | Antiproliferative activity against human LNCAP cells after 3 days by MTS assay, IC50=0.5 nM | 21438579 | |
| human MDA468 cells | Proliferation assay | 3 days | Antiproliferative activity against human MDA468 cells after 3 days by MTS assay, IC50=8 nM | 21438579 | |
| CGTH-W-1 | Growth inhibition assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50 = 0.005755 μM. | SANGER | ||
| QIMR-WIL | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 0.005708 μM. | SANGER | ||
| DEL | Growth inhibition assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 0.00546 μM. | SANGER | ||
| ES8 | Growth inhibition assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50 = 0.005268 μM. | SANGER | ||
| BE-13 | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50 = 0.004907 μM. | SANGER | ||
| H9 | Growth inhibition assay | Inhibition of human H9 cell growth in a cell viability assay, IC50 = 0.00488 μM. | SANGER | ||
| SW780 | Growth inhibition assay | Inhibition of human SW780 cell growth in a cell viability assay, IC50 = 0.004827 μM. | SANGER | ||
| NCI-SNU-1 | Growth inhibition assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50 = 0.004806 μM. | SANGER | ||
| CAMA-1 | Growth inhibition assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50 = 0.004771 μM. | SANGER | ||
| MOLT-4 | Growth inhibition assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 0.004306 μM. | SANGER | ||
| RPMI-8226 | Growth inhibition assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50 = 0.004148 μM. | SANGER | ||
| LAMA-84 | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 0.004033 μM. | SANGER | ||
| JVM-3 | Growth inhibition assay | Inhibition of human JVM-3 cell growth in a cell viability assay, IC50 = 0.003952 μM. | SANGER | ||
| GAMG | Growth inhibition assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50 = 0.003823 μM. | SANGER | ||
| MLMA | Growth inhibition assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 0.003313 μM. | SANGER | ||
| DB | Growth inhibition assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 0.003123 μM. | SANGER | ||
| CTB-1 | Growth inhibition assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50 = 0.002934 μM. | SANGER | ||
| 697 | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50 = 0.0017 μM. | SANGER | ||
| SK-NEP-1 | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 0.00149 μM. | SANGER | ||
| PA-1 | Growth inhibition assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50 = 0.00147 μM. | SANGER | ||
| K5 | Growth inhibition assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 0.001331 μM. | SANGER | ||
| H4 | Growth inhibition assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 0.001073 μM. | SANGER | ||
| TYK-nu | Growth inhibition assay | Inhibition of human TYK-nu cell growth in a cell viability assay, IC50 = 0.0007781 μM. | SANGER | ||
| HH | Growth inhibition assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 0.0006644 μM. | SANGER | ||
| MHH-PREB-1 | Growth inhibition assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50 = 0.0004955 μM. | SANGER | ||
| SBC-1 | Growth inhibition assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50 = 0.0004442 μM. | SANGER | ||
| Ramos-2G6-4C10 | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 0.0003419 μM. | SANGER | ||
| L-363 | Growth inhibition assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 0.000242 μM. | SANGER | ||
| HSC-4 | Growth inhibition assay | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50 = 0.0001134 μM. | SANGER | ||
| HEK293 | Function assay | Inhibition of FKBP12-independent human recombinant mTOR expressed in HEK293 cells using His6-S6K1 as a substrate by DELFIA assay, IC50 = 1.76 μM. | 21438579 | ||
| CHL-1 | Growth inhibition assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50 = 0.005856 μM. | SANGER | ||
| A2780 | Growth inhibition assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50 = 0.005882 μM. | SANGER | ||
| VA-ES-BJ | Growth inhibition assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50 = 0.005896 μM. | SANGER | ||
| BB65-RCC | Growth inhibition assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50 = 0.007004 μM. | SANGER | ||
| D-566MG | Growth inhibition assay | Inhibition of human D-566MG cell growth in a cell viability assay, IC50 = 0.007157 μM. | SANGER | ||
| HO-1-N-1 | Growth inhibition assay | Inhibition of human HO-1-N-1 cell growth in a cell viability assay, IC50 = 0.008201 μM. | SANGER | ||
| RS4-11 | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 0.00845 μM. | SANGER | ||
| PC-3 | Growth inhibition assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50 = 0.009142 μM. | SANGER | ||
| NB69 | Growth inhibition assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 0.009464 μM. | SANGER | ||
| HGC-27 | Growth inhibition assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50 = 0.009598 μM. | SANGER | ||
| NCI-H720 | Growth inhibition assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50 = 0.009617 μM. | SANGER | ||
| NCI-H292 | Growth inhibition assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50 = 0.009837 μM. | SANGER | ||
| A3-KAW | Growth inhibition assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 0.01043 μM. | SANGER | ||
| DU-4475 | Growth inhibition assay | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50 = 0.01173 μM. | SANGER | ||
| HuH-7 | Growth inhibition assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 0.01232 μM. | SANGER | ||
| J-RT3-T3-5 | Growth inhibition assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 0.01238 μM. | SANGER | ||
| VM-CUB-1 | Growth inhibition assay | Inhibition of human VM-CUB-1 cell growth in a cell viability assay, IC50 = 0.01267 μM. | SANGER | ||
| MOLT-16 | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 0.01284 μM. | SANGER | ||
| KG-1 | Growth inhibition assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 0.0129 μM. | SANGER | ||
| P12-ICHIKAWA | Growth inhibition assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50 = 0.01301 μM. | SANGER | ||
| ACN | Growth inhibition assay | Inhibition of human ACN cell growth in a cell viability assay, IC50 = 0.01302 μM. | SANGER | ||
| COLO-684 | Growth inhibition assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 0.01331 μM. | SANGER | ||
| T-24 | Growth inhibition assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50 = 0.01386 μM. | SANGER | ||
| AGS | Growth inhibition assay | Inhibition of human AGS cell growth in a cell viability assay, IC50 = 0.01411 μM. | SANGER | ||
| EW-13 | Growth inhibition assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50 = 0.01454 μM. | SANGER | ||
| SW962 | Growth inhibition assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 0.01559 μM. | SANGER | ||
| EW-11 | Growth inhibition assay | Inhibition of human EW-11 cell growth in a cell viability assay, IC50 = 0.0156 μM. | SANGER | ||
| RXF393 | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50 = 0.01566 μM. | SANGER | ||
| EoL-1-cell | Growth inhibition assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 0.0161 μM. | SANGER | ||
| KE-37 | Growth inhibition assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 0.01651 μM. | SANGER | ||
| U-118-MG | Growth inhibition assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 0.0167 μM. | SANGER | ||
| DOHH-2 | Growth inhibition assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50 = 0.01682 μM. | SANGER | ||
| OS-RC-2 | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50 = 0.01699 μM. | SANGER | ||
| NB7 | Growth inhibition assay | Inhibition of human NB7 cell growth in a cell viability assay, IC50 = 0.01788 μM. | SANGER | ||
| OC-314 | Growth inhibition assay | Inhibition of human OC-314 cell growth in a cell viability assay, IC50 = 0.01793 μM. | SANGER | ||
| HT-1080 | Growth inhibition assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50 = 0.01793 μM. | SANGER | ||
| MV-4-11 | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 0.01888 μM. | SANGER | ||
| MN-60 | Growth inhibition assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 0.01932 μM. | SANGER | ||
| A549 | Growth inhibition assay | Inhibition of human A549 cell growth in a cell viability assay, IC50 = 0.02019 μM. | SANGER | ||
| NTERA-S-cl-D1 | Growth inhibition assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50 = 0.02069 μM. | SANGER | ||
| NBsusSR | Growth inhibition assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50 = 0.02134 μM. | SANGER | ||
| HD-MY-Z | Growth inhibition assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50 = 0.0216 μM. | SANGER | ||
| EGI-1 | Growth inhibition assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50 = 0.02199 μM. | SANGER | ||
| SF126 | Growth inhibition assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50 = 0.02285 μM. | SANGER | ||
| HuO-3N1 | Growth inhibition assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 0.02302 μM. | SANGER | ||
| NCI-H1703 | Growth inhibition assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 0.02321 μM. | SANGER | ||
| NUGC-3 | Growth inhibition assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 0.02349 μM. | SANGER | ||
| ES1 | Growth inhibition assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50 = 0.02454 μM. | SANGER | ||
| MC116 | Growth inhibition assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50 = 0.02553 μM. | SANGER | ||
| HCC1419 | Growth inhibition assay | Inhibition of human HCC1419 cell growth in a cell viability assay, IC50 = 0.02585 μM. | SANGER | ||
| T98G | Growth inhibition assay | Inhibition of human T98G cell growth in a cell viability assay, IC50 = 0.02617 μM. | SANGER | ||
| A2058 | Growth inhibition assay | Inhibition of human A2058 cell growth in a cell viability assay, IC50 = 0.02655 μM. | SANGER | ||
| HT | Growth inhibition assay | Inhibition of human HT cell growth in a cell viability assay, IC50 = 0.02756 μM. | SANGER | ||
| PFSK-1 | Growth inhibition assay | Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50 = 0.02772 μM. | SANGER | ||
| EW-16 | Growth inhibition assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50 = 0.02857 μM. | SANGER | ||
| NCI-H82 | Growth inhibition assay | Inhibition of human NCI-H82 cell growth in a cell viability assay, IC50 = 0.02882 μM. | SANGER | ||
| LU-134-A | Growth inhibition assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 0.0289 μM. | SANGER | ||
| RPMI-8866 | Growth inhibition assay | Inhibition of human RPMI-8866 cell growth in a cell viability assay, IC50 = 0.03137 μM. | SANGER | ||
| BEN | Growth inhibition assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 0.0315 μM. | SANGER | ||
| ETK-1 | Growth inhibition assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50 = 0.03178 μM. | SANGER | ||
| SW1088 | Growth inhibition assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 0.03184 μM. | SANGER | ||
| BPH-1 | Growth inhibition assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50 = 0.03239 μM. | SANGER | ||
| ONS-76 | Growth inhibition assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50 = 0.03303 μM. | SANGER | ||
| EFO-27 | Growth inhibition assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50 = 0.03308 μM. | SANGER | ||
| GR-ST | Growth inhibition assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 0.03335 μM. | SANGER | ||
| MEL-HO | Growth inhibition assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50 = 0.03365 μM. | SANGER | ||
| MDA-MB-415 | Growth inhibition assay | Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50 = 0.03595 μM. | SANGER | ||
| ES4 | Growth inhibition assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50 = 0.03776 μM. | SANGER | ||
| HSC-3 | Growth inhibition assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50 = 0.03869 μM. | SANGER | ||
| IGROV-1 | Growth inhibition assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50 = 0.03879 μM. | SANGER | ||
| A204 | Growth inhibition assay | Inhibition of human A204 cell growth in a cell viability assay, IC50 = 0.03885 μM. | SANGER | ||
| RPMI-7951 | Growth inhibition assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50 = 0.03897 μM. | SANGER | ||
| LB2241-RCC | Growth inhibition assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50 = 0.03927 μM. | SANGER | ||
| CAL-39 | Growth inhibition assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50 = 0.04012 μM. | SANGER | ||
| DOK | Growth inhibition assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 0.04102 μM. | SANGER | ||
| YH-13 | Growth inhibition assay | Inhibition of human YH-13 cell growth in a cell viability assay, IC50 = 0.04108 μM. | SANGER | ||
| BV-173 | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50 = 0.04385 μM. | SANGER | ||
| NCI-H1793 | Growth inhibition assay | Inhibition of human NCI-H1793 cell growth in a cell viability assay, IC50 = 0.0457 μM. | SANGER | ||
| C32 | Growth inhibition assay | Inhibition of human C32 cell growth in a cell viability assay, IC50 = 0.04664 μM. | SANGER | ||
| RT-112 | Growth inhibition assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 0.04709 μM. | SANGER | ||
| A101D | Growth inhibition assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 0.04873 μM. | SANGER | ||
| EW-3 | Growth inhibition assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 0.04917 μM. | SANGER | ||
| HCE-T | Growth inhibition assay | Inhibition of human HCE-T cell growth in a cell viability assay, IC50 = 0.04917 μM. | SANGER | ||
| Mewo | Growth inhibition assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 0.04943 μM. | SANGER | ||
| KNS-62 | Growth inhibition assay | Inhibition of human KNS-62 cell growth in a cell viability assay, IC50 = 0.05037 μM. | SANGER | ||
| FTC-133 | Growth inhibition assay | Inhibition of human FTC-133 cell growth in a cell viability assay, IC50 = 0.05058 μM. | SANGER | ||
| KARPAS-45 | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 0.05134 μM. | SANGER | ||
| 786-0 | Growth inhibition assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 0.05169 μM. | SANGER | ||
| Daoy | Growth inhibition assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50 = 0.05172 μM. | SANGER | ||
| CHP-212 | Growth inhibition assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50 = 0.05243 μM. | SANGER | ||
| LU-139 | Growth inhibition assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50 = 0.05327 μM. | SANGER | ||
| HLE | Growth inhibition assay | Inhibition of human HLE cell growth in a cell viability assay, IC50 = 0.05394 μM. | SANGER | ||
| EM-2 | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 0.05421 μM. | SANGER | ||
| COR-L105 | Growth inhibition assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 0.05447 μM. | SANGER | ||
| NCI-H1355 | Growth inhibition assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 0.05588 μM. | SANGER | ||
| KASUMI-1 | Growth inhibition assay | Inhibition of human KASUMI-1 cell growth in a cell viability assay, IC50 = 0.05625 μM. | SANGER | ||
| MZ2-MEL | Growth inhibition assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 0.05687 μM. | SANGER | ||
| AN3-CA | Growth inhibition assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 0.05688 μM. | SANGER | ||
| NCI-H2126 | Growth inhibition assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 0.05801 μM. | SANGER | ||
| BCPAP | Growth inhibition assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50 = 0.05853 μM. | SANGER | ||
| MSTO-211H | Growth inhibition assay | Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50 = 0.06008 μM. | SANGER | ||
| SF295 | Growth inhibition assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50 = 0.06051 μM. | SANGER | ||
| ES5 | Growth inhibition assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50 = 0.06142 μM. | SANGER | ||
| NCI-H526 | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 0.06156 μM. | SANGER | ||
| LB1047-RCC | Growth inhibition assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 0.06305 μM. | SANGER | ||
| KS-1 | Growth inhibition assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 0.06346 μM. | SANGER | ||
| NCI-H1155 | Growth inhibition assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50 = 0.06357 μM. | SANGER | ||
| SK-UT-1 | Growth inhibition assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50 = 0.06413 μM. | SANGER | ||
| 23132-87 | Growth inhibition assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50 = 0.06466 μM. | SANGER | ||
| Hs-578-T | Growth inhibition assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 0.0659 μM. | SANGER | ||
| MEL-JUSO | Growth inhibition assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 0.06664 μM. | SANGER | ||
| HTC-C3 | Growth inhibition assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 0.06822 μM. | SANGER | ||
| CAKI-1 | Growth inhibition assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50 = 0.06872 μM. | SANGER | ||
| UM-UC-3 | Growth inhibition assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50 = 0.06921 μM. | SANGER | ||
| U-2-OS | Growth inhibition assay | Inhibition of human U-2-OS cell growth in a cell viability assay, IC50 = 0.07023 μM. | SANGER | ||
| D-336MG | Growth inhibition assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50 = 0.07595 μM. | SANGER | ||
| SK-MEL-24 | Growth inhibition assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 0.07702 μM. | SANGER | ||
| D-542MG | Growth inhibition assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50 = 0.07792 μM. | SANGER | ||
| Becker | Growth inhibition assay | Inhibition of human Becker cell growth in a cell viability assay, IC50 = 0.07989 μM. | SANGER | ||
| EFM-19 | Growth inhibition assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50 = 0.08146 μM. | SANGER | ||
| A4-Fuk | Growth inhibition assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50 = 0.08182 μM. | SANGER | ||
| TCCSUP | Growth inhibition assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 0.08233 μM. | SANGER | ||
| ES3 | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50 = 0.0851 μM. | SANGER | ||
| ES7 | Growth inhibition assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50 = 0.08585 μM. | SANGER | ||
| MEG-01 | Growth inhibition assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 0.08816 μM. | SANGER | ||
| G-401 | Growth inhibition assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50 = 0.08896 μM. | SANGER | ||
| UMC-11 | Growth inhibition assay | Inhibition of human UMC-11 cell growth in a cell viability assay, IC50 = 0.08945 μM. | SANGER | ||
| GT3TKB | Growth inhibition assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 0.09059 μM. | SANGER | ||
| MHH-ES-1 | Growth inhibition assay | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50 = 0.0919 μM. | SANGER | ||
| NCI-H1693 | Growth inhibition assay | Inhibition of human NCI-H1693 cell growth in a cell viability assay, IC50 = 0.09217 μM. | SANGER | ||
| Ca9-22 | Growth inhibition assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 0.09661 μM. | SANGER | ||
| NCI-H2030 | Growth inhibition assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50 = 0.09807 μM. | SANGER | ||
| NB14 | Growth inhibition assay | Inhibition of human NB14 cell growth in a cell viability assay, IC50 = 0.10019 μM. | SANGER | ||
| HC-1 | Growth inhibition assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50 = 0.1008 μM. | SANGER | ||
| SK-LU-1 | Growth inhibition assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50 = 0.10226 μM. | SANGER | ||
| SBC-5 | Growth inhibition assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50 = 0.10306 μM. | SANGER | ||
| NCI-H1437 | Growth inhibition assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50 = 0.1032 μM. | SANGER | ||
| S-117 | Growth inhibition assay | Inhibition of human S-117 cell growth in a cell viability assay, IC50 = 0.1053 μM. | SANGER | ||
| NCI-H1563 | Growth inhibition assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 0.10561 μM. | SANGER | ||
| SW620 | Growth inhibition assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50 = 0.10642 μM. | SANGER | ||
| GI-1 | Growth inhibition assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50 = 0.10688 μM. | SANGER | ||
| T47D | Growth inhibition assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 0.10746 μM. | SANGER | ||
| ME-180 | Growth inhibition assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50 = 0.10852 μM. | SANGER | ||
| NB5 | Growth inhibition assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50 = 0.11132 μM. | SANGER | ||
| KP-4 | Growth inhibition assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50 = 0.11563 μM. | SANGER | ||
| NCI-H661 | Growth inhibition assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50 = 0.11662 μM. | SANGER | ||
| CAL-62 | Growth inhibition assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50 = 0.11695 μM. | SANGER | ||
| RPMI-2650 | Growth inhibition assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50 = 0.11723 μM. | SANGER | ||
| M059J | Growth inhibition assay | Inhibition of human M059J cell growth in a cell viability assay, IC50 = 0.11777 μM. | SANGER | ||
| CAL-54 | Growth inhibition assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 0.11846 μM. | SANGER | ||
| DMS-114 | Growth inhibition assay | Inhibition of human DMS-114 cell growth in a cell viability assay, IC50 = 0.11943 μM. | SANGER | ||
| LOXIMVI | Growth inhibition assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 0.11987 μM. | SANGER | ||
| SF539 | Growth inhibition assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 0.12088 μM. | SANGER | ||
| IST-MEL1 | Growth inhibition assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 0.1232 μM. | SANGER | ||
| OVCAR-5 | Growth inhibition assay | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50 = 0.12369 μM. | SANGER | ||
| LU-99A | Growth inhibition assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 0.12493 μM. | SANGER | ||
| SK-N-AS | Growth inhibition assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50 = 0.12678 μM. | SANGER | ||
| SCC-15 | Growth inhibition assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50 = 0.12817 μM. | SANGER | ||
| COLO-800 | Growth inhibition assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 0.12939 μM. | SANGER | ||
| SK-MEL-28 | Growth inhibition assay | Inhibition of human SK-MEL-28 cell growth in a cell viability assay, IC50 = 0.13055 μM. | SANGER | ||
| NCI-H358 | Growth inhibition assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 0.13121 μM. | SANGER | ||
| MG-63 | Growth inhibition assay | Inhibition of human MG-63 cell growth in a cell viability assay, IC50 = 0.13434 μM. | SANGER | ||
| LN-405 | Growth inhibition assay | Inhibition of human LN-405 cell growth in a cell viability assay, IC50 = 0.13464 μM. | SANGER | ||
| RKO | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50 = 0.13548 μM. | SANGER | ||
| OVCAR-8 | Growth inhibition assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50 = 0.13634 μM. | SANGER | ||
| TGBC1TKB | Growth inhibition assay | Inhibition of human TGBC1TKB cell growth in a cell viability assay, IC50 = 0.13688 μM. | SANGER | ||
| KNS-81-FD | Growth inhibition assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50 = 0.13847 μM. | SANGER | ||
| KYSE-520 | Growth inhibition assay | Inhibition of human KYSE-520 cell growth in a cell viability assay, IC50 = 0.13862 μM. | SANGER | ||
| TGBC24TKB | Growth inhibition assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 0.14146 μM. | SANGER | ||
| SJSA-1 | Growth inhibition assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50 = 0.14331 μM. | SANGER | ||
| RD | Growth inhibition assay | Inhibition of human RD cell growth in a cell viability assay, IC50 = 0.14418 μM. | SANGER | ||
| HOS | Growth inhibition assay | Inhibition of human HOS cell growth in a cell viability assay, IC50 = 0.1455 μM. | SANGER | ||
| G-361 | Growth inhibition assay | Inhibition of human G-361 cell growth in a cell viability assay, IC50 = 0.14566 μM. | SANGER | ||
| J82 | Growth inhibition assay | Inhibition of human J82 cell growth in a cell viability assay, IC50 = 0.14803 μM. | SANGER | ||
| LXF-289 | Growth inhibition assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50 = 0.14834 μM. | SANGER | ||
| KALS-1 | Growth inhibition assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50 = 0.14918 μM. | SANGER | ||
| U-266 | Growth inhibition assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 0.15111 μM. | SANGER | ||
| NCI-H209 | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 0.15334 μM. | SANGER | ||
| PANC-10-05 | Growth inhibition assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50 = 0.15461 μM. | SANGER | ||
| KYSE-140 | Growth inhibition assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50 = 0.15573 μM. | SANGER | ||
| HEL | Growth inhibition assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 0.15761 μM. | SANGER | ||
| HCC70 | Growth inhibition assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 0.15777 μM. | SANGER | ||
| D-263MG | Growth inhibition assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50 = 0.15889 μM. | SANGER | ||
| A673 | Growth inhibition assay | Inhibition of human A673 cell growth in a cell viability assay, IC50 = 0.16072 μM. | SANGER | ||
| MZ7-mel | Growth inhibition assay | Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50 = 0.16074 μM. | SANGER | ||
| KYSE-270 | Growth inhibition assay | Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50 = 0.16428 μM. | SANGER | ||
| KOSC-2 | Growth inhibition assay | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50 = 0.16696 μM. | SANGER | ||
| NOMO-1 | Growth inhibition assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 0.16756 μM. | SANGER | ||
| SNU-423 | Growth inhibition assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50 = 0.17342 μM. | SANGER | ||
| SNU-387 | Growth inhibition assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 0.17525 μM. | SANGER | ||
| NCI-N87 | Growth inhibition assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50 = 0.17528 μM. | SANGER | ||
| HuO9 | Growth inhibition assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50 = 0.17744 μM. | SANGER | ||
| KYSE-410 | Growth inhibition assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50 = 0.1804 μM. | SANGER | ||
| NCI-H1648 | Growth inhibition assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 0.18154 μM. | SANGER | ||
| A427 | Growth inhibition assay | Inhibition of human A427 cell growth in a cell viability assay, IC50 = 0.18267 μM. | SANGER | ||
| SN12C | Growth inhibition assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50 = 0.18328 μM. | SANGER | ||
| LNCaP-Clone-FGC | Growth inhibition assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 0.18407 μM. | SANGER | ||
| SW13 | Growth inhibition assay | Inhibition of human SW13 cell growth in a cell viability assay, IC50 = 0.18571 μM. | SANGER | ||
| NCI-H1299 | Growth inhibition assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50 = 0.18583 μM. | SANGER | ||
| RVH-421 | Growth inhibition assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50 = 0.18731 μM. | SANGER | ||
| TE-6 | Growth inhibition assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 0.1889 μM. | SANGER | ||
| SW1710 | Growth inhibition assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50 = 0.18922 μM. | SANGER | ||
| BHT-101 | Growth inhibition assay | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50 = 0.19717 μM. | SANGER | ||
| NKM-1 | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50 = 0.19798 μM. | SANGER | ||
| HSC-2 | Growth inhibition assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50 = 0.19998 μM. | SANGER | ||
| TE-8 | Growth inhibition assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50 = 0.20019 μM. | SANGER | ||
| EW-1 | Growth inhibition assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50 = 0.20094 μM. | SANGER | ||
| NB10 | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50 = 0.20721 μM. | SANGER | ||
| NMC-G1 | Growth inhibition assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50 = 0.20822 μM. | SANGER | ||
| DBTRG-05MG | Growth inhibition assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50 = 0.21031 μM. | SANGER | ||
| 22RV1 | Growth inhibition assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 0.21194 μM. | SANGER | ||
| SK-MES-1 | Growth inhibition assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 0.21477 μM. | SANGER | ||
| HOP-92 | Growth inhibition assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50 = 0.22333 μM. | SANGER | ||
| KU-19-19 | Growth inhibition assay | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50 = 0.22839 μM. | SANGER | ||
| OE33 | Growth inhibition assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50 = 0.22972 μM. | SANGER | ||
| KMOE-2 | Growth inhibition assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50 = 0.23075 μM. | SANGER | ||
| OAW-42 | Growth inhibition assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50 = 0.24014 μM. | SANGER | ||
| OCI-AML2 | Growth inhibition assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 0.2416 μM. | SANGER | ||
| Detroit562 | Growth inhibition assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50 = 0.24192 μM. | SANGER | ||
| SW900 | Growth inhibition assay | Inhibition of human SW900 cell growth in a cell viability assay, IC50 = 0.24579 μM. | SANGER | ||
| D-392MG | Growth inhibition assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50 = 0.24835 μM. | SANGER | ||
| VMRC-RCZ | Growth inhibition assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50 = 0.24925 μM. | SANGER | ||
| GCIY | Growth inhibition assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50 = 0.25375 μM. | SANGER | ||
| CAL-72 | Growth inhibition assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 0.26469 μM. | SANGER | ||
| ES6 | Growth inhibition assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50 = 0.26642 μM. | SANGER | ||
| BFTC-909 | Growth inhibition assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50 = 0.27006 μM. | SANGER | ||
| SK-MEL-1 | Growth inhibition assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50 = 0.27111 μM. | SANGER | ||
| HN | Growth inhibition assay | Inhibition of human HN cell growth in a cell viability assay, IC50 = 0.27231 μM. | SANGER | ||
| KP-N-YS | Growth inhibition assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50 = 0.27292 μM. | SANGER | ||
| KNS-42 | Growth inhibition assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50 = 0.27293 μM. | SANGER | ||
| COLO-792 | Growth inhibition assay | Inhibition of human COLO-792 cell growth in a cell viability assay, IC50 = 0.27319 μM. | SANGER | ||
| CAL-33 | Growth inhibition assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50 = 0.27442 μM. | SANGER | ||
| NCI-H2452 | Growth inhibition assay | Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50 = 0.27712 μM. | SANGER | ||
| NCI-H1838 | Growth inhibition assay | Inhibition of human NCI-H1838 cell growth in a cell viability assay, IC50 = 0.2785 μM. | SANGER | ||
| ZR-75-30 | Growth inhibition assay | Inhibition of human ZR-75-30 cell growth in a cell viability assay, IC50 = 0.28283 μM. | SANGER | ||
| SK-HEP-1 | Growth inhibition assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50 = 0.28292 μM. | SANGER | ||
| ACHN | Growth inhibition assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50 = 0.28315 μM. | SANGER | ||
| YKG-1 | Growth inhibition assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 0.28388 μM. | SANGER | ||
| D-247MG | Growth inhibition assay | Inhibition of human D-247MG cell growth in a cell viability assay, IC50 = 0.28825 μM. | SANGER | ||
| COLO-680N | Growth inhibition assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50 = 0.2902 μM. | SANGER | ||
| EW-24 | Growth inhibition assay | Inhibition of human EW-24 cell growth in a cell viability assay, IC50 = 0.29231 μM. | SANGER | ||
| KGN | Growth inhibition assay | Inhibition of human KGN cell growth in a cell viability assay, IC50 = 0.29451 μM. | SANGER | ||
| MIA-PaCa-2 | Growth inhibition assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50 = 0.29587 μM. | SANGER | ||
| SiHa | Growth inhibition assay | Inhibition of human SiHa cell growth in a cell viability assay, IC50 = 0.29993 μM. | SANGER | ||
| MS-1 | Growth inhibition assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 0.30154 μM. | SANGER | ||
| DK-MG | Growth inhibition assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50 = 0.30508 μM. | SANGER | ||
| HL-60 | Growth inhibition assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 0.30635 μM. | SANGER | ||
| NCI-H446 | Growth inhibition assay | Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50 = 0.30806 μM. | SANGER | ||
| KINGS-1 | Growth inhibition assay | Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50 = 0.3103 μM. | SANGER | ||
| EW-22 | Growth inhibition assay | Inhibition of human EW-22 cell growth in a cell viability assay, IC50 = 0.31117 μM. | SANGER | ||
| HT-3 | Growth inhibition assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 0.31593 μM. | SANGER | ||
| TI-73 | Growth inhibition assay | Inhibition of human TI-73 cell growth in a cell viability assay, IC50 = 0.31672 μM. | SANGER | ||
| PC-14 | Growth inhibition assay | Inhibition of human PC-14 cell growth in a cell viability assay, IC50 = 0.31899 μM. | SANGER | ||
| ABC-1 | Growth inhibition assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50 = 0.32037 μM. | SANGER | ||
| AU565 | Growth inhibition assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50 = 0.32111 μM. | SANGER | ||
| IST-MES1 | Growth inhibition assay | Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50 = 0.32517 μM. | SANGER | ||
| LK-2 | Growth inhibition assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 0.32518 μM. | SANGER | ||
| TK10 | Growth inhibition assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50 = 0.32537 μM. | SANGER | ||
| TE-5 | Growth inhibition assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50 = 0.3257 μM. | SANGER | ||
| 8505C | Growth inhibition assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 0.32614 μM. | SANGER | ||
| SW626 | Growth inhibition assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 0.32669 μM. | SANGER | ||
| 647-V | Growth inhibition assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50 = 0.33189 μM. | SANGER | ||
| 639-V | Growth inhibition assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 0.34085 μM. | SANGER | ||
| TE-11 | Growth inhibition assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 0.34108 μM. | SANGER | ||
| NCI-H1304 | Growth inhibition assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50 = 0.34564 μM. | SANGER | ||
| JEG-3 | Growth inhibition assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 0.34655 μM. | SANGER | ||
| OCUB-M | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50 = 0.35038 μM. | SANGER | ||
| CAL-27 | Growth inhibition assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50 = 0.35051 μM. | SANGER | ||
| MDA-MB-175-VII | Growth inhibition assay | Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay, IC50 = 0.3543 μM. | SANGER | ||
| HuP-T3 | Growth inhibition assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 0.35658 μM. | SANGER | ||
| HEC-1 | Growth inhibition assay | Inhibition of human HEC-1 cell growth in a cell viability assay, IC50 = 0.36355 μM. | SANGER | ||
| BHY | Growth inhibition assay | Inhibition of human BHY cell growth in a cell viability assay, IC50 = 0.3648 μM. | SANGER | ||
| NCI-H28 | Growth inhibition assay | Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50 = 0.36823 μM. | SANGER | ||
| JAR | Growth inhibition assay | Inhibition of human JAR cell growth in a cell viability assay, IC50 = 0.38211 μM. | SANGER | ||
| DSH1 | Growth inhibition assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50 = 0.38616 μM. | SANGER | ||
| PSN1 | Growth inhibition assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50 = 0.38725 μM. | SANGER | ||
| SCH | Growth inhibition assay | Inhibition of human SCH cell growth in a cell viability assay, IC50 = 0.38863 μM. | SANGER | ||
| C-33-A | Growth inhibition assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50 = 0.39213 μM. | SANGER | ||
| 769-P | Growth inhibition assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 0.39425 μM. | SANGER | ||
| Calu-3 | Growth inhibition assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50 = 0.40206 μM. | SANGER | ||
| NCI-H2170 | Growth inhibition assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50 = 0.4047 μM. | SANGER | ||
| AM-38 | Growth inhibition assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 0.40809 μM. | SANGER | ||
| 8-MG-BA | Growth inhibition assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50 = 0.40843 μM. | SANGER | ||
| SNB75 | Growth inhibition assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50 = 0.4126 μM. | SANGER | ||
| U251 | Growth inhibition assay | Inhibition of human U251 cell growth in a cell viability assay, IC50 = 0.41985 μM. | SANGER | ||
| CAL-51 | Growth inhibition assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 0.42586 μM. | SANGER | ||
| D-423MG | Growth inhibition assay | Inhibition of human D-423MG cell growth in a cell viability assay, IC50 = 0.4302 μM. | SANGER | ||
| SW982 | Growth inhibition assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50 = 0.44068 μM. | SANGER | ||
| A498 | Growth inhibition assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 0.44076 μM. | SANGER | ||
| KYSE-180 | Growth inhibition assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 0.45093 μM. | SANGER | ||
| NCI-H1092 | Growth inhibition assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 0.45219 μM. | SANGER | ||
| M14 | Growth inhibition assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 0.46306 μM. | SANGER | ||
| LC-2-ad | Growth inhibition assay | Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50 = 0.46687 μM. | SANGER | ||
| SK-OV-3 | Growth inhibition assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50 = 0.46759 μM. | SANGER | ||
| HAL-01 | Growth inhibition assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50 = 0.46909 μM. | SANGER | ||
| NCI-H727 | Growth inhibition assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 0.47186 μM. | SANGER | ||
| MFE-280 | Growth inhibition assay | Inhibition of human MFE-280 cell growth in a cell viability assay, IC50 = 0.47429 μM. | SANGER | ||
| LU-135 | Growth inhibition assay | Inhibition of human LU-135 cell growth in a cell viability assay, IC50 = 0.47755 μM. | SANGER | ||
| BB49-HNC | Growth inhibition assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 0.48208 μM. | SANGER | ||
| RH-1 | Growth inhibition assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50 = 0.48724 μM. | SANGER | ||
| SW1783 | Growth inhibition assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 0.48745 μM. | SANGER | ||
| EW-18 | Growth inhibition assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 0.49124 μM. | SANGER | ||
| SNU-449 | Growth inhibition assay | Inhibition of human SNU-449 cell growth in a cell viability assay, IC50 = 0.49252 μM. | SANGER | ||
| NH-12 | Growth inhibition assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 0.49319 μM. | SANGER | ||
| SCC-4 | Growth inhibition assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 0.49591 μM. | SANGER | ||
| OMC-1 | Growth inhibition assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50 = 0.501 μM. | SANGER | ||
| SW756 | Growth inhibition assay | Inhibition of human SW756 cell growth in a cell viability assay, IC50 = 0.50718 μM. | SANGER | ||
| HCC1806 | Growth inhibition assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50 = 0.50891 μM. | SANGER | ||
| WM-115 | Growth inhibition assay | Inhibition of human WM-115 cell growth in a cell viability assay, IC50 = 0.51096 μM. | SANGER | ||
| LB831-BLC | Growth inhibition assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50 = 0.51457 μM. | SANGER | ||
| EC-GI-10 | Growth inhibition assay | Inhibition of human EC-GI-10 cell growth in a cell viability assay, IC50 = 0.5201 μM. | SANGER | ||
| GB-1 | Growth inhibition assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 0.53479 μM. | SANGER | ||
| SF268 | Growth inhibition assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50 = 0.54005 μM. | SANGER | ||
| NB13 | Growth inhibition assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50 = 0.54084 μM. | SANGER | ||
| SH-4 | Growth inhibition assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 0.54115 μM. | SANGER | ||
| KYSE-510 | Growth inhibition assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50 = 0.54347 μM. | SANGER | ||
| KYSE-450 | Growth inhibition assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50 = 0.54664 μM. | SANGER | ||
| RERF-LC-MS | Growth inhibition assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50 = 0.5499 μM. | SANGER | ||
| NCI-H1650 | Growth inhibition assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 0.55213 μM. | SANGER | ||
| GI-ME-N | Growth inhibition assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50 = 0.55384 μM. | SANGER | ||
| EKVX | Growth inhibition assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50 = 0.55387 μM. | SANGER | ||
| DU-145 | Growth inhibition assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50 = 0.55743 μM. | SANGER | ||
| NCI-H1651 | Growth inhibition assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 0.56343 μM. | SANGER | ||
| MCF7 | Growth inhibition assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 0.56969 μM. | SANGER | ||
| MFM-223 | Growth inhibition assay | Inhibition of human MFM-223 cell growth in a cell viability assay, IC50 = 0.5774 μM. | SANGER | ||
| KM-H2 | Growth inhibition assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 0.57756 μM. | SANGER | ||
| ECC10 | Growth inhibition assay | Inhibition of human ECC10 cell growth in a cell viability assay, IC50 = 0.5851 μM. | SANGER | ||
| C2BBe1 | Growth inhibition assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50 = 0.58687 μM. | SANGER | ||
| SK-PN-DW | Growth inhibition assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50 = 0.59283 μM. | SANGER | ||
| MPP-89 | Growth inhibition assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 0.59386 μM. | SANGER | ||
| MKN45 | Growth inhibition assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 0.59903 μM. | SANGER | ||
| SK-MEL-2 | Growth inhibition assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50 = 0.60178 μM. | SANGER | ||
| GMS-10 | Growth inhibition assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 0.61623 μM. | SANGER | ||
| SW48 | Growth inhibition assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 0.62038 μM. | SANGER | ||
| 5637 | Growth inhibition assay | Inhibition of human 5637 cell growth in a cell viability assay, IC50 = 0.62466 μM. | SANGER | ||
| P30-OHK | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 0.64188 μM. | SANGER | ||
| HCC2218 | Growth inhibition assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50 = 0.6562 μM. | SANGER | ||
| SK-MEL-3 | Growth inhibition assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 0.66112 μM. | SANGER | ||
| A431 | Growth inhibition assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 0.66405 μM. | SANGER | ||
| MKN1 | Growth inhibition assay | Inhibition of human MKN1 cell growth in a cell viability assay, IC50 = 0.67663 μM. | SANGER | ||
| NCI-H1792 | Growth inhibition assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50 = 0.67992 μM. | SANGER | ||
| MDA-MB-231 | Growth inhibition assay | Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50 = 0.68339 μM. | SANGER | ||
| PANC-08-13 | Growth inhibition assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 0.69499 μM. | SANGER | ||
| SW1463 | Growth inhibition assay | Inhibition of human SW1463 cell growth in a cell viability assay, IC50 = 0.70213 μM. | SANGER | ||
| NCI-H2228 | Growth inhibition assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 0.71151 μM. | SANGER | ||
| HPAF-II | Growth inhibition assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 0.71172 μM. | SANGER | ||
| TE-12 | Growth inhibition assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50 = 0.7127 μM. | SANGER | ||
| SCC-25 | Growth inhibition assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 0.72229 μM. | SANGER | ||
| KY821 | Growth inhibition assay | Inhibition of human KY821 cell growth in a cell viability assay, IC50 = 0.7258 μM. | SANGER | ||
| NOS-1 | Growth inhibition assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 0.72704 μM. | SANGER | ||
| DMS-273 | Growth inhibition assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50 = 0.72972 μM. | SANGER | ||
| SNU-C2B | Growth inhibition assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50 = 0.74246 μM. | SANGER | ||
| KYSE-70 | Growth inhibition assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50 = 0.74477 μM. | SANGER | ||
| COLO-741 | Growth inhibition assay | Inhibition of human COLO-741 cell growth in a cell viability assay, IC50 = 0.74907 μM. | SANGER | ||
| NCI-H520 | Growth inhibition assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50 = 0.75859 μM. | SANGER | ||
| NCI-H1573 | Growth inhibition assay | Inhibition of human NCI-H1573 cell growth in a cell viability assay, IC50 = 0.76634 μM. | SANGER | ||
| IGR-1 | Growth inhibition assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 0.76716 μM. | SANGER | ||
| H-EMC-SS | Growth inhibition assay | Inhibition of human H-EMC-SS cell growth in a cell viability assay, IC50 = 0.77051 μM. | SANGER | ||
| MDA-MB-453 | Growth inhibition assay | Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50 = 0.77688 μM. | SANGER | ||
| NCI-H23 | Growth inhibition assay | Inhibition of human NCI-H23 cell growth in a cell viability assay, IC50 = 0.77846 μM. | SANGER | ||
| NCI-H1581 | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 0.77909 μM. | SANGER | ||
| SKG-IIIa | Growth inhibition assay | Inhibition of human SKG-IIIa cell growth in a cell viability assay, IC50 = 0.77912 μM. | SANGER | ||
| NCI-H810 | Growth inhibition assay | Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50 = 0.78045 μM. | SANGER | ||
| SW1990 | Growth inhibition assay | Inhibition of human SW1990 cell growth in a cell viability assay, IC50 = 0.78173 μM. | SANGER | ||
| BFTC-905 | Growth inhibition assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50 = 0.78421 μM. | SANGER | ||
| BALL-1 | Growth inhibition assay | Inhibition of human BALL-1 cell growth in a cell viability assay, IC50 = 0.78606 μM. | SANGER | ||
| BxPC-3 | Growth inhibition assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 0.78715 μM. | SANGER | ||
| CAL-12T | Growth inhibition assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50 = 0.79984 μM. | SANGER | ||
| UACC-257 | Growth inhibition assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 0.81865 μM. | SANGER | ||
| HT-1376 | Growth inhibition assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50 = 0.82639 μM. | SANGER | ||
| ChaGo-K-1 | Growth inhibition assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50 = 0.84188 μM. | SANGER | ||
| CTV-1 | Growth inhibition assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 0.85473 μM. | SANGER | ||
| LB771-HNC | Growth inhibition assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 0.85515 μM. | SANGER | ||
| KARPAS-299 | Growth inhibition assay | Inhibition of human KARPAS-299 cell growth in a cell viability assay, IC50 = 0.87357 μM. | SANGER | ||
| KM12 | Growth inhibition assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 0.878 μM. | SANGER | ||
| CAPAN-1 | Growth inhibition assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 0.88166 μM. | SANGER | ||
| RO82-W-1 | Growth inhibition assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50 = 0.89683 μM. | SANGER | ||
| LCLC-97TM1 | Growth inhibition assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 0.90513 μM. | SANGER | ||
| EPLC-272H | Growth inhibition assay | Inhibition of human EPLC-272H cell growth in a cell viability assay, IC50 = 0.92117 μM. | SANGER | ||
| L-428 | Growth inhibition assay | Inhibition of human L-428 cell growth in a cell viability assay, IC50 = 0.95936 μM. | SANGER | ||
| MKN28 | Growth inhibition assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 0.97996 μM. | SANGER | ||
| BT-474 | Growth inhibition assay | Inhibition of human BT-474 cell growth in a cell viability assay, IC50 = 0.99197 μM. | SANGER | ||
| SK-N-DZ | Growth inhibition assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 0.99775 μM. | SANGER | ||
| BT-20 | Growth inhibition assay | Inhibition of human BT-20 cell growth in a cell viability assay, IC50 = 1.00073 μM. | SANGER | ||
| MMAC-SF | Growth inhibition assay | Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50 = 1.00439 μM. | SANGER | ||
| NCI-H596 | Growth inhibition assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50 = 1.03978 μM. | SANGER | ||
| CAL-120 | Growth inhibition assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50 = 1.0404 μM. | SANGER | ||
| SW954 | Growth inhibition assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50 = 1.13951 μM. | SANGER | ||
| AsPC-1 | Growth inhibition assay | Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50 = 1.15211 μM. | SANGER | ||
| A172 | Growth inhibition assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 1.15653 μM. | SANGER | ||
| SK-N-FI | Growth inhibition assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50 = 1.16634 μM. | SANGER | ||
| RMG-I | Growth inhibition assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50 = 1.1686 μM. | SANGER | ||
| HDLM-2 | Growth inhibition assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 1.16874 μM. | SANGER | ||
| Ca-Ski | Growth inhibition assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 1.18041 μM. | SANGER | ||
| NY | Growth inhibition assay | Inhibition of human NY cell growth in a cell viability assay, IC50 = 1.18605 μM. | SANGER | ||
| TE-1 | Growth inhibition assay | Inhibition of human TE-1 cell growth in a cell viability assay, IC50 = 1.2082 μM. | SANGER | ||
| NCI-H2342 | Growth inhibition assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 1.20932 μM. | SANGER | ||
| GOTO | Growth inhibition assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 1.2159 μM. | SANGER | ||
| NCI-H226 | Growth inhibition assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 1.24003 μM. | SANGER | ||
| NCI-H1623 | Growth inhibition assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50 = 1.27466 μM. | SANGER | ||
| LCLC-103H | Growth inhibition assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50 = 1.28798 μM. | SANGER | ||
| EFO-21 | Growth inhibition assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50 = 1.29934 μM. | SANGER | ||
| NCI-H747 | Growth inhibition assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 1.31678 μM. | SANGER | ||
| CaR-1 | Growth inhibition assay | Inhibition of human CaR-1 cell growth in a cell viability assay, IC50 = 1.32211 μM. | SANGER | ||
| HCC38 | Growth inhibition assay | Inhibition of human HCC38 cell growth in a cell viability assay, IC50 = 1.32574 μM. | SANGER | ||
| BT-549 | Growth inhibition assay | Inhibition of human BT-549 cell growth in a cell viability assay, IC50 = 1.3617 μM. | SANGER | ||
| COLO-679 | Growth inhibition assay | Inhibition of human COLO-679 cell growth in a cell viability assay, IC50 = 1.3815 μM. | SANGER | ||
| NCI-SNU-5 | Growth inhibition assay | Inhibition of human NCI-SNU-5 cell growth in a cell viability assay, IC50 = 1.38647 μM. | SANGER | ||
| NB12 | Growth inhibition assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 1.39558 μM. | SANGER | ||
| NCI-H2291 | Growth inhibition assay | Inhibition of human NCI-H2291 cell growth in a cell viability assay, IC50 = 1.40653 μM. | SANGER | ||
| OVCAR-4 | Growth inhibition assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 1.4508 μM. | SANGER | ||
| MDA-MB-361 | Growth inhibition assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 1.45389 μM. | SANGER | ||
| GAK | Growth inhibition assay | Inhibition of human GAK cell growth in a cell viability assay, IC50 = 1.50665 μM. | SANGER | ||
| SAS | Growth inhibition assay | Inhibition of human SAS cell growth in a cell viability assay, IC50 = 1.54774 μM. | SANGER | ||
| NCI-H441 | Growth inhibition assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50 = 1.58956 μM. | SANGER | ||
| KLE | Growth inhibition assay | Inhibition of human KLE cell growth in a cell viability assay, IC50 = 1.5909 μM. | SANGER | ||
| HuCCT1 | Growth inhibition assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 1.59983 μM. | SANGER | ||
| LS-1034 | Growth inhibition assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 1.64213 μM. | SANGER | ||
| Saos-2 | Growth inhibition assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50 = 1.66455 μM. | SANGER | ||
| NCI-H1975 | Growth inhibition assay | Inhibition of human NCI-H1975 cell growth in a cell viability assay, IC50 = 1.69685 μM. | SANGER | ||
| CFPAC-1 | Growth inhibition assay | Inhibition of human CFPAC-1 cell growth in a cell viability assay, IC50 = 1.7227 μM. | SANGER | ||
| LU-65 | Growth inhibition assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 1.77769 μM. | SANGER | ||
| DoTc2-4510 | Growth inhibition assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50 = 1.77868 μM. | SANGER | ||
| CP50-MEL-B | Growth inhibition assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50 = 1.83992 μM. | SANGER | ||
| PANC-03-27 | Growth inhibition assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 1.84292 μM. | SANGER | ||
| IA-LM | Growth inhibition assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 1.89734 μM. | SANGER | ||
| ML-2 | Growth inhibition assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 1.89978 μM. | SANGER | ||
| ATN-1 | Growth inhibition assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 1.90199 μM. | SANGER | ||
| D-502MG | Growth inhibition assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50 = 1.91132 μM. | SANGER | ||
| 8305C | Growth inhibition assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 2.03006 μM. | SANGER | ||
| MC-IXC | Growth inhibition assay | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50 = 2.03153 μM. | SANGER | ||
| SW684 | Growth inhibition assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50 = 2.04455 μM. | SANGER | ||
| LS-123 | Growth inhibition assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50 = 2.17606 μM. | SANGER | ||
| GCT | Growth inhibition assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 2.30304 μM. | SANGER | ||
| IST-SL1 | Growth inhibition assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 2.33042 μM. | SANGER | ||
| SW837 | Growth inhibition assay | Inhibition of human SW837 cell growth in a cell viability assay, IC50 = 2.43277 μM. | SANGER | ||
| COR-L88 | Growth inhibition assay | Inhibition of human COR-L88 cell growth in a cell viability assay, IC50 = 2.46133 μM. | SANGER | ||
| HCC1954 | Growth inhibition assay | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50 = 2.53005 μM. | SANGER | ||
| U-87-MG | Growth inhibition assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 2.58229 μM. | SANGER | ||
| UACC-62 | Growth inhibition assay | Inhibition of human UACC-62 cell growth in a cell viability assay, IC50 = 2.62026 μM. | SANGER | ||
| HuP-T4 | Growth inhibition assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50 = 2.68282 μM. | SANGER | ||
| U031 | Growth inhibition assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 2.70111 μM. | SANGER | ||
| NCI-H2087 | Growth inhibition assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 2.71769 μM. | SANGER | ||
| HCC1395 | Growth inhibition assay | Inhibition of human HCC1395 cell growth in a cell viability assay, IC50 = 2.77564 μM. | SANGER | ||
| NCI-H650 | Growth inhibition assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50 = 2.83212 μM. | SANGER | ||
| HT-1197 | Growth inhibition assay | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50 = 2.85285 μM. | SANGER | ||
| COR-L23 | Growth inhibition assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50 = 2.91652 μM. | SANGER | ||
| ALL-PO | Growth inhibition assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 2.92007 μM. | SANGER | ||
| KYSE-150 | Growth inhibition assay | Inhibition of human KYSE-150 cell growth in a cell viability assay, IC50 = 2.93449 μM. | SANGER | ||
| NB6 | Growth inhibition assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 2.94381 μM. | SANGER | ||
| NCI-H1395 | Growth inhibition assay | Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50 = 2.96085 μM. | SANGER | ||
| RH-18 | Growth inhibition assay | Inhibition of human RH-18 cell growth in a cell viability assay, IC50 = 3.00634 μM. | SANGER | ||
| HCE-4 | Growth inhibition assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 3.01069 μM. | SANGER | ||
| NCI-H1755 | Growth inhibition assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 3.05649 μM. | SANGER | ||
| KURAMOCHI | Growth inhibition assay | Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50 = 3.09323 μM. | SANGER | ||
| YAPC | Growth inhibition assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 3.11291 μM. | SANGER | ||
| LB2518-MEL | Growth inhibition assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50 = 3.17578 μM. | SANGER | ||
| LB373-MEL-D | Growth inhibition assay | Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50 = 3.1894 μM. | SANGER | ||
| LoVo | Growth inhibition assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 3.25446 μM. | SANGER | ||
| NCI-H1048 | Growth inhibition assay | Inhibition of human NCI-H1048 cell growth in a cell viability assay, IC50 = 3.28063 μM. | SANGER | ||
| SW1573 | Growth inhibition assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50 = 3.39065 μM. | SANGER | ||
| HCT-116 | Growth inhibition assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 3.41438 μM. | SANGER | ||
| NEC8 | Growth inhibition assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 3.53767 μM. | SANGER | ||
| JVM-2 | Growth inhibition assay | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50 = 3.5842 μM. | SANGER | ||
| NCI-H2347 | Growth inhibition assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 3.59686 μM. | SANGER | ||
| C8166 | Growth inhibition assay | Inhibition of human C8166 cell growth in a cell viability assay, IC50 = 3.59699 μM. | SANGER | ||
| CAS-1 | Growth inhibition assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 3.61667 μM. | SANGER | ||
| no-11 | Growth inhibition assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50 = 3.62102 μM. | SANGER | ||
| A704 | Growth inhibition assay | Inhibition of human A704 cell growth in a cell viability assay, IC50 = 3.68806 μM. | SANGER | ||
| CP66-MEL | Growth inhibition assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50 = 3.74023 μM. | SANGER | ||
| NCI-H1770 | Growth inhibition assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50 = 3.80523 μM. | SANGER | ||
| BB30-HNC | Growth inhibition assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 3.83852 μM. | SANGER | ||
| DMS-79 | Growth inhibition assay | Inhibition of human DMS-79 cell growth in a cell viability assay, IC50 = 3.84658 μM. | SANGER | ||
| DJM-1 | Growth inhibition assay | Inhibition of human DJM-1 cell growth in a cell viability assay, IC50 = 3.84886 μM. | SANGER | ||
| Calu-6 | Growth inhibition assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50 = 3.8595 μM. | SANGER | ||
| HCC2998 | Growth inhibition assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50 = 3.86497 μM. | SANGER | ||
| NCI-H2122 | Growth inhibition assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50 = 3.98583 μM. | SANGER | ||
| HCC1569 | Growth inhibition assay | Inhibition of human HCC1569 cell growth in a cell viability assay, IC50 = 4.22325 μM. | SANGER | ||
| SCC-9 | Growth inhibition assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 4.24321 μM. | SANGER | ||
| UACC-893 | Growth inhibition assay | Inhibition of human UACC-893 cell growth in a cell viability assay, IC50 = 4.24635 μM. | SANGER | ||
| KU812 | Growth inhibition assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50 = 4.48868 μM. | SANGER | ||
| HOP-62 | Growth inhibition assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50 = 4.52942 μM. | SANGER | ||
| CAL-85-1 | Growth inhibition assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 4.54395 μM. | SANGER | ||
| SHP-77 | Growth inhibition assay | Inhibition of human SHP-77 cell growth in a cell viability assay, IC50 = 4.61889 μM. | SANGER | ||
| NCI-H2405 | Growth inhibition assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50 = 4.71275 μM. | SANGER | ||
| OVCAR-3 | Growth inhibition assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 4.91737 μM. | SANGER | ||
| HT-144 | Growth inhibition assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 4.93929 μM. | SANGER | ||
| FADU | Growth inhibition assay | Inhibition of human FADU cell growth in a cell viability assay, IC50 = 4.95088 μM. | SANGER | ||
| TGBC11TKB | Growth inhibition assay | Inhibition of human TGBC11TKB cell growth in a cell viability assay, IC50 = 5.02982 μM. | SANGER | ||
| NCI-H2052 | Growth inhibition assay | Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50 = 5.06257 μM. | SANGER | ||
| GP5d | Growth inhibition assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50 = 5.08943 μM. | SANGER | ||
| KP-N-YN | Growth inhibition assay | Inhibition of human KP-N-YN cell growth in a cell viability assay, IC50 = 5.17794 μM. | SANGER | ||
| LS-411N | Growth inhibition assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 5.41851 μM. | SANGER | ||
| MZ1-PC | Growth inhibition assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 5.77734 μM. | SANGER | ||
| HT55 | Growth inhibition assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 6.07538 μM. | SANGER | ||
| MKN7 | Growth inhibition assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50 = 6.15543 μM. | SANGER | ||
| TE-9 | Growth inhibition assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 6.17025 μM. | SANGER | ||
| LAN-6 | Growth inhibition assay | Inhibition of human LAN-6 cell growth in a cell viability assay, IC50 = 6.31122 μM. | SANGER | ||
| MHH-NB-11 | Growth inhibition assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 6.50631 μM. | SANGER | ||
| COLO-829 | Growth inhibition assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 6.51542 μM. | SANGER | ||
| ESS-1 | Growth inhibition assay | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50 = 6.57447 μM. | SANGER | ||
| RCC10RGB | Growth inhibition assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 6.73892 μM. | SANGER | ||
| D-283MED | Growth inhibition assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 6.86372 μM. | SANGER | ||
| C3A | Growth inhibition assay | Inhibition of human C3A cell growth in a cell viability assay, IC50 = 7.03211 μM. | SANGER | ||
| COLO-678 | Growth inhibition assay | Inhibition of human COLO-678 cell growth in a cell viability assay, IC50 = 7.13662 μM. | SANGER | ||
| OAW-28 | Growth inhibition assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50 = 7.19267 μM. | SANGER | ||
| A388 | Growth inhibition assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 7.61434 μM. | SANGER | ||
| G-402 | Growth inhibition assay | Inhibition of human G-402 cell growth in a cell viability assay, IC50 = 7.81597 μM. | SANGER | ||
| NB17 | Growth inhibition assay | Inhibition of human NB17 cell growth in a cell viability assay, IC50 = 8.26304 μM. | SANGER | ||
| COLO-668 | Growth inhibition assay | Inhibition of human COLO-668 cell growth in a cell viability assay, IC50 = 8.4187 μM. | SANGER | ||
| MFH-ino | Growth inhibition assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50 = 8.58367 μM. | SANGER | ||
| LS-513 | Growth inhibition assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50 = 8.59 μM. | SANGER | ||
| MOLT-13 | Growth inhibition assay | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50 = 8.59511 μM. | SANGER | ||
| SW872 | Growth inhibition assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50 = 8.91481 μM. | SANGER | ||
| RCM-1 | Growth inhibition assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50 = 9.09658 μM. | SANGER | ||
| SW1116 | Growth inhibition assay | Inhibition of human SW1116 cell growth in a cell viability assay, IC50 = 9.10722 μM. | SANGER | ||
| NCI-H69 | Growth inhibition assay | Inhibition of human NCI-H69 cell growth in a cell viability assay, IC50 = 9.61206 μM. | SANGER | ||
| Capan-2 | Growth inhibition assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 10.0202 μM. | SANGER | ||
| SW948 | Growth inhibition assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 10.4142 μM. | SANGER | ||
| SW1417 | Growth inhibition assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 10.794 μM. | SANGER | ||
| HCC1937 | Growth inhibition assay | Inhibition of human HCC1937 cell growth in a cell viability assay, IC50 = 11.322 μM. | SANGER | ||
| NCI-H510A | Growth inhibition assay | Inhibition of human NCI-H510A cell growth in a cell viability assay, IC50 = 11.9708 μM. | SANGER | ||
| MDA-MB-157 | Growth inhibition assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 13.9409 μM. | SANGER | ||
| T84 | Growth inhibition assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 14.3826 μM. | SANGER | ||
| NCI-H2029 | Growth inhibition assay | Inhibition of human NCI-H2029 cell growth in a cell viability assay, IC50 = 14.4817 μM. | SANGER | ||
| TE-10 | Growth inhibition assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50 = 14.494 μM. | SANGER | ||
| NCI-H1993 | Growth inhibition assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50 = 15.3309 μM. | SANGER | ||
| NCI-H630 | Growth inhibition assay | Inhibition of human NCI-H630 cell growth in a cell viability assay, IC50 = 15.6115 μM. | SANGER | ||
| HCT-15 | Growth inhibition assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50 = 15.9411 μM. | SANGER | ||
| no-10 | Growth inhibition assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50 = 16.1357 μM. | SANGER | ||
| K-562 | Growth inhibition assay | Inhibition of human K-562 cell growth in a cell viability assay, IC50 = 16.7384 μM. | SANGER | ||
| COLO-824 | Growth inhibition assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 18.1783 μM. | SANGER | ||
| COLO-320-HSR | Growth inhibition assay | Inhibition of human COLO-320-HSR cell growth in a cell viability assay, IC50 = 18.3911 μM. | SANGER | ||
| CCRF-CEM | Growth inhibition assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 18.5294 μM. | SANGER | ||
| NCI-H2009 | Growth inhibition assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50 = 18.7815 μM. | SANGER | ||
| HT-29 | Growth inhibition assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50 = 18.8874 μM. | SANGER | ||
| CW-2 | Growth inhibition assay | Inhibition of human CW-2 cell growth in a cell viability assay, IC50 = 21.4137 μM. | SANGER | ||
| HCC1187 | Growth inhibition assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 24.6168 μM. | SANGER | ||
| SK-LMS-1 | Growth inhibition assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50 = 27.4476 μM. | SANGER | ||
| SJRH30 | Growth inhibition assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 36.6109 μM. | SANGER | ||
| HUTU-80 | Growth inhibition assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50 = 43.7905 μM. | SANGER | ||
| 他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい | |||||
生物活性
| 製品説明 | Temsirolimus is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis. | ||
|---|---|---|---|
| Targets |
|
| In Vitro | ||||
| In vitro | In the absence of FKBP12, Temsirolimus potently inhibits mTOR kinase activity with IC50 of 1.76 μM, similar to that of rapamycin with IC50 of 1.74 μM. Temsirolimus treatment at nanomolar concentrations (10 nM to <5 μM) displays a modest and selective antiproliferative activity via FKBP12-dependent mechanism, but can completely inhibit the proliferation of a broad panel of tumor cells at low micromolar concentrations (5-15 μM), involving FKBP12-independent suppression of mTOR signaling. Temsirolimus treatment at micromolar but not nanomolar concentrations (20 μM) causes a marked decline in global protein synthesis and disassembly of polyribosomes, accompanied by rapid increase in the phosphorylation of translation elongation factor eEF2 and the translation initiation factor eIF2A. [1] Temsirolimus inhibits the phosphorylation of ribosomal protein S6, more potently in PTEN-positive DU145 cells than in PTEN-negative PC-3 cells, and inhibits cell growth and clonogenic survival of both cells in a concentration-dependent manner. [2] Temsirolimus (100 ng/mL) potently inhibits proliferation and induces apoptosis in primary human lymphoblastic leukemia (ALL) cells. [3] | |||
|---|---|---|---|---|
| Kinase Assay | In vitro assay of mTOR catalytic activity | |||
| The Flag-tagged wild-type human mTOR (Flag-mTOR) DNA constructs are transiently transfected into HEK293 cells. Protein extraction and purification of Flag-mTOR are carried out 48 hours later. In vitro kinase assays of purified Flag-mTOR in the presence of various concentrations of Temsirolimus without FKBP12 are performed in 96-well plate and detected by dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) using His6-S6K1 as the substrate. Enzymes is first diluted in kinase assay buffer (10 mM Hepes (pH 7.4), 50 mM NaCl, 50 mM β-glycerophosphate, 10 mM MnCl2, 0.5 mM DTT, 0.25 μM microcystin LR, and 100 μg/mL BSA). To each well, 12 μL of the diluted enzyme is mixed briefly with 0.5 μL Temsirolimus. The kinase reaction is initiated by adding 12.5 μL kinase assay buffer containing ATP and His6-S6K to give a final reaction volume of 25 μL containing 800 ng/mL FLAG-mTOR, 100 μM ATP, and 1.25 μM His6-S6K. The reaction plate is incubated for 2 hours (linear at 1-6 hours) at room temperature with gentle shaking and then terminated by adding 25 μL Stop buffer (20 mM Hepes (pH 7.4), 20 mM EDTA, and 20 mM EGTA). The DELFIA detection of the phosphorylated (Thr-389) His6-S6K is performed at room temperature using a monoclonal anti-P(T389)-p70S6K antibody labeled with Europium-N1-ITC (Eu) (10.4 Eu per antibody). 45 μL of the terminated kinase reaction mixture is transferred to a MaxiSorp plate containing 55 μL PBS. The His6-S6K is allowed to attach for 2 hours after which the wells are aspirated and washed once with PBS. 100 μL of DELFIA buffer with 40 ng/mL Eu-P(T389)-S6K antibody is added. The antibody binding is continued for 1 hour with gentle agitation. The wells are then aspirated and washed four times with PBS containing 0.05% Tween 20 (PBST). 100 μL of DELFIA Enhancement solution is added to each well and the plates are read in a PerkinElmer Victor model plate reader. | ||||
| 細胞実験 | 細胞株 | A549, H157, H460, H446, HCT116, HT29, SW480, DLD1, Caco2, LNCap, DU145, MDA468, MDA231, HEK293, and PC3-MM2 | ||
| 濃度 | Dissolved in DMSO, final concentrations ~20 μM | |||
| 反応時間 | 72 hours | |||
| 実験の流れ | Cells are exposed to various concentrations of Temsirolimus for 72 hours. After treatment, viable cell densities are determined by MTS dye conversion using CellTiter AQ assay kit. |
|||
| 実験結果図 | Methods | Biomarkers | 結果図 | PMID |
| Western blot | p-rS6 / rS6 / p-AKT /AKT p-mTOR / mTOR / p-S6 / S6 / p-4E-BP1 / 4E-BP1 |
|
22039466 | |
| Immunofluorescence | NRF2 |
|
22848625 | |
| Growth inhibition assay | Cell viability Cell growth (HGC-3 cells) |
|
22039466 | |
| In Vivo | ||
| In Vivo | In the NOD/SCID xenograft models with human ALL, Temsirolimus treatment at 10 mg/kg/day produces a decrease in peripheral blood blasts and in splenomegaly [3] Administration of Temsirolimus (20 mg/kg i.p. 5 days/week) significantly delays the growth of DAOY xenografts by 160% after 1 week and 240% after 2 weeks, compared with controls. Single high-dose of Temsirolimus (100 mg/kg i.p) treatment induces 37% regression of tumor volume within 1 week. Temsirolimus treatment for 2 weeks also delays the growth of rapamycin-resistant U251 xenografts by 148%. [4] Inhibition of mTOR by Temsirolimus improves performance on four different behavioral tasks and decreases aggregate formation in a mouse model of Huntington disease. [5] Administration of Temsirolimus induces significant dose-dependent, antitumor responses against subcutaneous growth of 8226, OPM-2, and U266 xenografts with ED50 of 20 mg/kg and 2 mg/kg for 8226 and OPM-2, respectively, which are associated with inhibited proliferation and angiogenesis, induction of apoptosis, and reduction in tumor cell size. [6] | |
|---|---|---|
| 動物実験 | 動物モデル | Female athymic nude mice injected s.c. with DAOY, or U251 cells |
| 投与量 | 20 mg/kg | |
| 投与経路 | Injection daily 5 times per week | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05773326 | Recruiting | High Grade Glioma|Glioma|Glioma Malignant|Glioblastoma |
Nader Sanai|Barrow Neurological Institute|Ivy Brain Tumor Center|St. Joseph''s Hospital and Medical Center Phoenix |
May 15 2023 | Early Phase 1 |
| NCT01653067 | Unknown status | Diffuse Large B-Cell Lymphoma |
Mathias Witzens-Harig|Johannes Gutenberg University Mainz|Technical University of Munich|Ludwig-Maximilians - University of Munich|University Hospital Ulm|University Hospital Erlangen|Charite University Berlin Germany|University Hospital Freiburg|Johann Wolfgang Goethe University Hospital|University Hospital Heidelberg |
September 2012 | Phase 2 |
| NCT02093598 | Completed | Carcinoma Endometrioid|mTOR Protein |
MedSIR |
May 2012 | Phase 2 |
化学情報
| 分子量 | 1030.29 | 化学式 | C56H87NO16 |
| CAS No. | 162635-04-3 | SDF | Download Temsirolimus SDFをダウンロードする |
| Smiles | CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC | ||
| 保管 | |||
|
In vitro |
DMSO : 100 mg/mL ( (97.06 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。) Ethanol : 100 mg/mL Water : Insoluble |
モル濃度計算器 |
|
in vivo Add solvents to the product individually and in order. |
投与溶液組成計算機 | ||||
実験計算
投与溶液組成計算機(クリア溶液)
ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）
mg/kg
g
μL
匹
ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結果：
投与溶媒濃度： mg/ml;
DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )
投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。
投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。
注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。
技術サポート
ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。
他に質問がある場合は、お気軽にお問い合わせください。
* 必須
Tags: Temsirolimusを買う | Temsirolimus ic50 | Temsirolimus供給者 | Temsirolimusを購入する | Temsirolimus費用 | Temsirolimus生産者 | オーダーTemsirolimus | Temsirolimus化学構造 | Temsirolimus分子量 | Temsirolimus代理店
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間